Clinical Trial Update: Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial of BXCL501 (sublingual dexmedetomidine) for agitation in the emergency department, including schizophrenia-spectrum and bipolar disorder i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• BXCL501 (dexmedetomidine)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Agitation, Schizophrenia | Phase 4 | Status: WITHDRAWN